Psoriatic arthritis TYK2 inhibitor oral therapy FDA approval with autoimmune disease treatment
RegulatoryBusiness Wire

Bristol Myers Squibb Receives FDA Approval for Sotyktu in Psoriatic Arthritis

BMS announces FDA approval of deucravacitinib (Sotyktu) for adults with active psoriatic arthritis, expanding its indication beyond plaque psoriasis.

Bristol Myers Squibb today announced that the FDA has approved Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis. In the Phase 3 POETYK PSA-1 and PSA-2 trials, deucravacitinib demonstrated significant improvements in ACR20 response rates and other measures of disease activity compared to placebo. The safety profile was consistent with that observed in plaque psoriasis, with no new safety signals identified. This approval expands Sotyktu's indication and provides a new oral treatment option for psoriatic arthritis patients.

Original Source

Business Wire
Share:

Previous

Sanofi Receives FDA Approval for Tolebrutinib in Non-Relapsing Secondary Progressive MS

Next

Roche Reports Phase 3 Results for Giredestrant in ER-Positive HER2-Negative Breast Cancer